DEFINITIVE CONTRACT
Active75F40126C00066
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$2.7M
obligated · signed 2 months ago
EO 14398 BAA TARGETED POLYMER-LIPID NANOPARTICLE PLATFORM FOR BIOPROTAC MEDIATED DEGRADATION OF ONCOFUSION PROTEINS IN EWING SARCOMA
Performance timeline
Start
Sep 15, 2026
Current end
Sep 23, 2028
Potential end
Sep 23, 2031
with all options
Loading status
Estimated start: Sep 23, 2030
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE
Contract 75F40126C00066
UEI
GM1XX56LEP58
Parent Company
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE
Capabilities & Certifications
Headquarters Location
Congressional District: 03
Current Obligation
$2,682,546
Base + Exercised Options
$2,682,546
Total Ceiling Value
$6,954,936
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Place of Performance
Congressional District: 03
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.